Clinical protocols for the treatment of gastrointestinal cancer

胃肠道癌是癌症相关死亡的主要原因之一， 美国的目前的治疗选择仅限于手术、化疗、放疗 因此，迫切需要新的靶向治疗和分子靶向治疗以及新的治疗选择。我们有 NCI-20-C-0022：VB-111在 与Nivolumab联合治疗转移性结直肠癌（mCRC）患者。 NCI-19-C-0033：Nivolumab（抗PD 1）、他达拉非和口服万古霉素治疗 难治性原发性肝癌或肝转移癌患者 结直肠癌或胰腺癌; NCI-17-C-0092：Pexa-Vec溶瘤药物的I/II期研究 病毒联合免疫检查点抑制治疗难治性结直肠癌 NCI-16-C-0135：联合免疫检查点抑制与 肝细胞癌（HCC）或胆道癌受试者的消融治疗 (BTC)19 C 0094 A：Durvalumab，贝伐单抗， 曲美木单抗和经动脉化疗栓塞（TACE）治疗肝细胞癌受试者 NCI-21-C-0030：靶向GPC 3的I期研究 CAR-T细胞治疗晚期GPC 3表达肝细胞癌（HCC）; NCI-20-C-0152： 曲美替尼（MEK抑制剂）和羟氯喹（HCQ）联合用药的II期研究 自噬抑制剂在KRAS突变难治性胆道癌患者中的应用 （BTC）.

Gastrointestinal cancer represents one of the major reasons for tumor related death in the United States. Current treatment options are limited to surgery, chemotherapy, radiation therapy and molecular targeted therapy and new treatment options are urgently needed. We have been enrolling patients on the following protocols:NCI-20-C-0022: Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC). NCI-19-C-0033:Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers; NCI-17-C-0092: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer; NCI-16-C-0135: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) ;.19C0094 A: A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC).NCI-21-C-0030: Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC); NCI-20-C-0152: Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).